# OnCo record gi-innovation (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/gi-innovation/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "gi-innovation" ;
  schema:name "GI Innovation"@en ;
  schema:alternateName "GI Innovation, Inc."@en ;
  schema:description "GI Innovation is a South Korea-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific fusion proteins GI-101, GI-102 and GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma."@en ;
  schema:url <https://onco.cc/companies/gi-innovation/>, <https://www.gi-innovation.com> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.gi-innovation.com>, <https://clinicaltrials.gov/search?lead=GI%20Innovation%2C%20Inc.> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "KR" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/lenvatinib/> ;
  onco:trials <https://onco.cc/trials/nct07172802/>, <https://onco.cc/trials/nct05824975/>, <https://onco.cc/trials/nct04977453/> .